Archives

ET AL. V. JANSSEN BIOTECH, INC., ET AL., CASE NO. 19-CV-14146 (D.N.J.)

LGN represents end payor plaintiffs who allege an unlawful scheme by defendants to prolong their monopoly in the market for Zytiga® (abiraterone acetate), a drug used to treat patients with prostate cancer. LGN seeks to recover damages for a proposed class of end payors who purchased Zytiga® indirectly from defendants beginning December 13, 2016 through the present. The case is pending in the United States District Court for the District of New Jersey before the Honorable James B. Clark.

CASE NO. 1:15-CV-02937 (N.D. ILL.)

LGN represents plaintiffs who allege that Kraft Foods and Mondelez Global manipulated cash wheat prices and wheat futures contracts. The United States District Court for the Northern District of Illinois certified the plaintiff class in January 2020.  The case is pending before the Honorable John F. Ness and is proceeding toward trial.

CASE NO. 1:05-MD-01720 (E.D.N.Y.)

LGN represents a class of merchants that accepted Visa and MasterCard credit and debit cards in the United States. Plaintiffs allege that Visa, MasterCard and their member banks conspired to impose and maintain interchange fees, or “swipe fees,” on merchants as a condition of using their cards. In December 2019, the United States District Court for the Eastern District of New York approved a settlement between the plaintiff monetary relief class and all defendants for over $6 billion. Some members of the monetary relief class have appealed the District Court’s approval of the settlement, and that appeal is pending.

LGN represents end payor plaintiffs who allege that drug companies entered into an anticompetitive scheme to restrain competition in the market for Humira and its biosimilar competitors.  This action is pending in the United States District Court of the Northern District of Illinois before the Honorable Manish S. Shah.